TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33377792

Group type: EXPERIMENTAL
Intervention: Prospective observational study (POS)
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Retrospective cohort study (RCS)
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Randomized clinical trial (RCT)
Number of subjects: 4033
Study: 35892247

Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32538746

Group type: EXPERIMENTAL
Intervention: TACE in combination with lobaplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: TACE in combination with cisplatin (Control group)
Number of subjects: 0
Study: 35506388

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers
Number of subjects: 448

Group type: COMPARATOR
Intervention: Intensive blood pressure arm
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Top tertile of WMH progression
Number of subjects: 448
Study: 33057999

Group type: EXPERIMENTAL
Intervention: Physician-directed replacement (any choice of steroid, dose or route)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed-dose dexamethasone 8 mg oral before starting docetaxel
Number of subjects: 60
Study: 34694223

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FC; 1,000 mg, single dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Iron sucrose (IS; 200 mg every 48 hours until covering the total iron deficit or discharge)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 104
Study: 34853109

Group type: EXPERIMENTAL
Intervention: Perineural catheter (PNC) for postoperative pain relief
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard care for postoperative pain relief
Number of subjects: 14
Study: 32053119

Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention (CARE+ Corrections), participants received weekly or daily SMS text messages for 6 months.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention (CARE+ Corrections) with customized message content.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no SMS text messaging intervention).
Number of subjects: 110
Study: 33538999

Group type: EXPERIMENTAL
Intervention: Patients' Own Medicines (POMs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual dispensing (Control)
Number of subjects: 30
Study: 34586476

Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with silicone stent tube (SST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic DCR without silicone stent tube (NSST)
Number of subjects: 60
Study: 34151513

Group type: EXPERIMENTAL
Intervention: Linear mixed model (LMM) on log-transformed biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear mixed model (LMM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed model
Number of subjects: 0
Study: 32883807

Group type: EXPERIMENTAL
Intervention: Starting Early Program (prenatal and postpartum nutrition counseling and nutrition parenting support groups)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Starting Early Program (with varying attendance)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Starting Early Program
Number of subjects: 566
Study: 37560168

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program using a mobile app
Number of subjects: 50

Group type: COMPARATOR
Intervention: Home-based rehabilitation program using an exercise pamphlet
Number of subjects: 50
Study: 35081422

Group type: EXPERIMENTAL
Intervention: pRMGIC (30% ethylene glycol methacrylate phosphate)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Fuji II LC (control)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: pRMGIC
Number of subjects: 192
Study: 33452758

Group type: EXPERIMENTAL
Intervention: High BMI
Number of subjects: 14261

Group type: EXPERIMENTAL
Intervention: Short stature
Number of subjects: 14261

Group type: EXPERIMENTAL
Intervention: Male offspring
Number of subjects: 14261

Group type: EXPERIMENTAL
Intervention: Lower wealth
Number of subjects: 14261

Group type: EXPERIMENTAL
Intervention: Lower husband's education
Number of subjects: 14261

Group type: EXPERIMENTAL
Intervention: Age and parity
Number of subjects: 14261

Group type: EXPERIMENTAL
Intervention: Socio-economic status
Number of subjects: 14261
Study: 32213517

Group type: EXPERIMENTAL
Intervention: 12-week group cognitive-behavioural therapy (CBT) programme
Number of subjects: 99

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 99
Study: 33714551

Group type: EXPERIMENTAL
Intervention: Digital post analogs of 0.9 mm, 1.0 mm, and 1.14 mm in diameter at depths of 3 mm, 4 mm, and 5 mm from the radiographic apex
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Parallel‐sided posts inserted to a depth equaling the height of the crown
Number of subjects: 122

Group type: COMPARATOR
Intervention: Contralateral molars
Number of subjects: 122
Study: 32812129

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser combined with intralesional steroid (Triamcinolone acetonide)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser combined with intralesional botulinum toxin type A
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nd:YAG laser alone
Number of subjects: 45
Study: 36243181

Group type: EXPERIMENTAL
Intervention: Closed Loop Stimulation (CLS) with conventional upper sensor rate programming
Number of subjects: 17

Group type: COMPARATOR
Intervention: No rate-adaptive pacing (RAP)
Number of subjects: 17
Study: 34407545

Group type: COMPARATOR
Intervention: 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indefinite ibrutinib plus 6 cycles of rituximab (IR)
Number of subjects: 0
Study: 32429961

Group type: EXPERIMENTAL
Intervention: Social network intervention designed to tackle loneliness
Number of subjects: 0
Study: 35170392

Group type: EXPERIMENTAL
Intervention: Salinomycin (69 mg/kg feed)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Encapsulated Butyrate (EB) (500 mg/kg)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Control (no dietary supplement)
Number of subjects: 672
Study: 34111367

Group type: EXPERIMENTAL
Intervention: ActionHealthNYC program participants
Number of subjects: 0
Study: 32552850

Group type: EXPERIMENTAL
Intervention: Unpredictable gait perturbation training (Perturb group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Walking-only training (NonPerturb group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Follow-up assessments for balance confidence and community integration
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Satisfaction with perturbation training
Number of subjects: 21
Study: 35089345

Group type: EXPERIMENTAL
Intervention: 9 h TIB
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 8 h TIB
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 5 h TIB
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 6.5 h TIB
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 5 h TIB + 1 h nap
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 5 h TIB + 1.5 h nap
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 6.5 h TIB + 1.5 h nap
Number of subjects: 194
Study: 32450901

Group type: EXPERIMENTAL
Intervention: Training programme (5-day training including evidence-based medicine training module and application of the guideline)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care (publicly available guideline)
Number of subjects: 26
Study: 36240954

Group type: EXPERIMENTAL
Intervention: Repeated low-level red-light (RLRL) therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single-vision spectacle (SVS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RLRL therapy
Number of subjects: 120
Study: 33944631

Group type: EXPERIMENTAL
Intervention: Lung-RADS version 1.1
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Lung-RADS version 1.0
Number of subjects: 2813
Study: 32173063

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study: 35041452

Group type: EXPERIMENTAL
Intervention: IVUS-guided postdilation
Number of subjects: 2325

Group type: COMPARATOR
Intervention: Angiography-guided postdilation
Number of subjects: 2325

Group type: COMPARATOR
Intervention: Angiography-guided without postdilation
Number of subjects: 2325
Study: 35922823

Group type: EXPERIMENTAL
Intervention: Endoscopic intervention (endoscopic bulking injections)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard NHS surgical intervention (colposuspension, autologous fascial sling or artificial urinary sphincter)
Number of subjects: 250
Study: 33500258

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors (treatment duration: median 11.1 months)
Number of subjects: 52
Study: 32083290

Group type: EXPERIMENTAL
Intervention: Adjuvant S1 therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX regimen as adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study: 36165504

Group type: EXPERIMENTAL
Intervention: LAVA TQ
Number of subjects: 144

Group type: COMPARATOR
Intervention: CAT
Number of subjects: 144
Study: 33591032

Group type: EXPERIMENTAL
Intervention: ADASCs alone (3 × 10⁶ cells/1 mL) in Group 1 (n = 5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 120-μm decellularized corneal stroma lamina in Group 2 (n = 5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 120-μm lamina recellularized with ADASCs (1 × 10⁶ cells/1 mL) in Group 3 (n = 4)
Number of subjects: 14
Study: 32468892

Group type: EXPERIMENTAL
Intervention: SB4, SB2, and SB5 (biosimilars of ETN, INF, and ADA)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: Biosimilars combined (SB4, SB2, SB5)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: Reference products combined (ETN, INF, ADA)
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: All-treatments-combined
Number of subjects: 1709

Group type: EXPERIMENTAL
Intervention: SB2 + INF
Number of subjects: 1709
Study: 34271931

Group type: EXPERIMENTAL
Intervention: Cultural beliefs on breastfeeding cessation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local explanatory model of child diarrhoea
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Perceptions of diarrhoea treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Integration of local explanatory model in healthcare
Number of subjects: 55
Study: 35462408

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized treatment based on patient goals and values
Number of subjects: 0
Study: 33915252

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 33317375

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Prehypertension
Number of subjects: 1031
Study: 35906004

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure
Number of subjects: 0
Study: 33410583

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study: 34591549

Group type: EXPERIMENTAL
Intervention: panic‐focused psychodynamic psychotherapy (PFPP)
Number of subjects: 217

Group type: COMPARATOR
Intervention: panic control treatment (PCT)
Number of subjects: 217
Study: 35477633

Group type: EXPERIMENTAL
Intervention: LEM5 (5 mg)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: LEM10 (10 mg)
Number of subjects: 949

Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 949
Study: 35770861

Group type: EXPERIMENTAL
Intervention: Multinutrient treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 35123779

Group type: EXPERIMENTAL
Intervention: 1‐flunixin group (1‐FLU, n = 26) with a single administration of transdermal flunixin meglumine at disbudding
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 2‐flunin group (2‐FLU, n = 24) with 2 administrations of transdermal flunixin meglumine, the first treatment at disbudding and the second 6 h after disbudding
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CON, n = 27) received a placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All groups (1‐FLU, 2‐FLU, CON)
Number of subjects: 71
Study: 34675472

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.1% ophthalmic solution, administered once daily for 14–84 days
Number of subjects: 568

Group type: COMPARATOR
Intervention: Placebo (vehicle), administered once daily for 14–84 days
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.1% ophthalmic solution
Number of subjects: 568

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 568
Study: 33148672

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy after breast-conserving surgery (BCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-conserving surgery (BCS) only
Number of subjects: 0
Study: 32599131

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to abdominal area (treatment group A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel applied to upper arms/shoulders (treatment group B)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: IVPT method using FTC diffusion system, SM membrane, and phosphate buffer without surfactant
Number of subjects: 3
Study: 35774276

Group type: EXPERIMENTAL
Intervention: Oral administration of sweet almond oil (126 ml over 7 sessions in 2 weeks, 18 ml every other day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Abdominal massage with sweet almond oil (same amount as oral group, during 7 sessions in 2 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral administration of sweet almond oil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 90
Study: 33974129

Group type: EXPERIMENTAL
Intervention: 150 µg/d iodine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 300 µg/d iodine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 34034960

Group type: EXPERIMENTAL
Intervention: Fast adaptation (10 h wear from the first day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Gradual adaptation (4 h on the first day, increasing by 2 h daily until 10 h)
Number of subjects: 74
Study: 34099007

Group type: EXPERIMENTAL
Intervention: Low-intensity psychosocial telemental interventions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 33788479

Group type: EXPERIMENTAL
Intervention: Tongdu Tiaowei
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tongdu Yangxin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tongdu Tiaozang
Number of subjects: 90
Study: 35002557

Group type: EXPERIMENTAL
Intervention: Inhaled Budesonide (BUD) 2 mL, 0.25‐mg/mL suspension, inhalation, twice daily for 5 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (humidified distilled sterile water inhalation, 2 mL)
Number of subjects: 120
Study: 36401514

Group type: EXPERIMENTAL
Intervention: Stented group (37 patients)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Unstented group (35 patients)
Number of subjects: 72
Study: 34452681

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy Team (BTT) intervention consisting of individual information-gathering sessions followed by 12 weeks of group ERP and concurrent home-based coaching sessions
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy Team (BTT) intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 47
Study: 32744578

Group type: EXPERIMENTAL
Intervention: ET followed by RT (E+R; n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RT followed by ET (R+E; n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C; n=10)
Number of subjects: 30
Study: 36175919

Group type: EXPERIMENTAL
Intervention: tDCS + WMT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tDCS + simple response training (SRT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham tDCS + WMT
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham tDCS + SRT
Number of subjects: 120
Study: 32551958

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional recovery after surgery (Control)
Number of subjects: 84
Study: 35974157

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation with PEEP 8 cmH2O (No-RM), n = 12
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sustained inflation (SI), n = 15
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dynamic PEEP strategy (maximum PEEP 14 or 20 cmH2O), n = 41
Number of subjects: 68

Group type: COMPARATOR
Intervention: All strategies (No-RM, SI, DynPEEP)
Number of subjects: 68
Study: 33464316

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 4109

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 4109

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 4109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4109
Study: 32372186

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri LR92 DSM 26866 (1 × 10^8 CFU daily for 4 weeks)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo (9% glucose solution for 4 weeks)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri LR92 DSM 26866
Number of subjects: 145
Study: 33198432

Group type: EXPERIMENTAL
Intervention: Visual aid (educational visual aid provided prior to simulation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no visual aid provided)
Number of subjects: 44
Study: 33230190

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT, n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Computer games (TAU, n = 21)
Number of subjects: 42
Study: 37313689

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 34229284

Group type: EXPERIMENTAL
Intervention: Active iTBS stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study: 32958483

Group type: EXPERIMENTAL
Intervention: Patient-targeted and GP-targeted feedback regarding the depression screening results
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Only GP-targeted feedback
Number of subjects: 1074

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1074
Study: 35850078

Group type: EXPERIMENTAL
Intervention: Birth environment room
Number of subjects: 680

Group type: COMPARATOR
Intervention: Standard birth room
Number of subjects: 680
Study: 33763126

Group type: EXPERIMENTAL
Intervention: Neurological music therapy
Number of subjects: 40
Study: 34001205

Group type: EXPERIMENTAL
Intervention: Peri-articular liposomal bupivacaine plus bupivacaine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride alone
Number of subjects: 0
Study: 36063826

Group type: EXPERIMENTAL
Intervention: EV 4 mg/d
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: EV 6 mg/d
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: EV 9 mg/d
Number of subjects: 88
Study: 33641238

Group type: EXPERIMENTAL
Intervention: PR‐Tac with continental breakfast
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: IR‐Tac with continental breakfast
Number of subjects: 36
Study: 35635201

Group type: COMPARATOR
Intervention: Daily application of negatively charged polystyrene microspheres (NCMs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Application of negatively charged polystyrene microspheres (NCMs) three times per week
Number of subjects: 30
Study: 33358539

Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: hydrocortisone
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study: 32819529

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 0
Study: 35042096

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 34861869

Group type: EXPERIMENTAL
Intervention: Support provided to participants during the trial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Addressing participants' concerns and ethical issues
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anonymous concerns reported to the trial team
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethical strategies employed
Number of subjects: 20
Study: 35079762

Group type: EXPERIMENTAL
Intervention: sbeII wheat bread
Number of subjects: 19

Group type: COMPARATOR
Intervention: WT control bread
Number of subjects: 19
Study: 33198634

Group type: EXPERIMENTAL
Intervention: Patient-centred deprescribing intervention (2-hour training of PCPs, use of a validated deprescribing algorithm, shared decision-making)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Patient-centred deprescribing intervention
Number of subjects: 334
Study: 34915659

Group type: EXPERIMENTAL
Intervention: Semilunar-tunnel flap technique (SLTT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified papilla preserved technique (MPPT)
Number of subjects: 20
Study: 32171252

Group type: EXPERIMENTAL
Intervention: Network-offered training programs focusing on best practice guideline-oriented use of antibiotics
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Peer communication within primary care networks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Social influence processes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ARena intervention components
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Network peer exchange
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Expectations from stakeholders regarding networks
Number of subjects: 45
Study: 36171184

Group type: EXPERIMENTAL
Intervention: EXERCISE (n = 25), 4 months·yr ‐1 for 5 years
Number of subjects: 64

Group type: COMPARATOR
Intervention: CONTROL (n = 26)
Number of subjects: 64